Aurobindo Pharma Ltd. (AUROPHARMA) fundamentals
Aurobindo Pharma Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as AUROPHARMA (ISIN INE406A01037). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Aurobindo Pharma Ltd. does
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.
Valuation and market data
| Last close | ₹1590.00 |
|---|---|
| Market capitalisation | ₹92,306 crore |
| Enterprise value | ₹87,695 crore |
| P/E (TTM) | 26.35 |
| Price to book | 2.44 |
| Price to sales (TTM) | 1.53 |
| Book value per share | ₹652.55 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Jul 19 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹11,759 crore | ₹3,164 crore | ₹2,415 crore | 41.58 |
| Mar 2025 | ₹11,261 crore | ₹2,358 crore | ₹1,747 crore | 29.97 |
| Mar 2024 | ₹11,262 crore | ₹2,403 crore | ₹1,900 crore | 33.35 |
| Mar 2023 | ₹8,901 crore | ₹1,631 crore | ₹1,242 crore | 20.94 |
| Mar 2022 | ₹11,958 crore | ₹1,637 crore | ₹1,455 crore | 24.83 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 51.9% |
|---|---|
| Foreign institutions (FII) | 17.4% |
| Mutual funds | 16.3% |
| Other domestic institutions | 8.1% |
| Retail and others | 6.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.